强生公司宣布，其Tecvayli®联合Darzalex Faspro®的治疗方案已获得美国食品药品监督管理局（FDA）的批准，用于治疗复发或难治性多发性骨髓瘤患者。
这一批准意义重大，因为它为患者提供了一种潜在的全新护理标准，该方案甚至可在疾病的第二线治疗阶段就尽早使用。
强生公司宣布，其Tecvayli®联合Darzalex Faspro®的治疗方案已获得美国食品药品监督管理局（FDA）的批准，用于治疗复发或难治性多发性骨髓瘤患者。
这一批准意义重大，因为它为患者提供了一种潜在的全新护理标准，该方案甚至可在疾病的第二线治疗阶段就尽早使用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.